TY - JOUR
T1 - Quality of life changes after chronic total occlusion angioplasty in patients with baseline refractory angina
AU - OPEN-CTO Study Group
AU - Hirai, Taishi
AU - Aaron Grantham, J.
AU - Sapontis, James
AU - Cohen, David J.
AU - Marso, Steven P.
AU - Lombardi, William
AU - Karmpaliotis, Dimitri
AU - Moses, Jeffrey
AU - Nicholson, William J.
AU - Pershad, Ashish
AU - Michael Wyman, R.
AU - Spaedy, Anthony
AU - Cook, Stephen
AU - Doshi, Parag
AU - Federici, Robert
AU - Nugent, Karen
AU - Gosch, Kensey L.
AU - Spertus, John A.
AU - Salisbury, Adam C.
N1 - Funding Information:
Dr Grantham received speaking fees and honoraria from Boston Scientific, Abbott Vascular, and Asahi Intecc; institutional research grant support from Boston Scientific; and part-time employment and equity in Corindus Vascular Robotics. Dr Sapontis received speaking fees and honoraria from Boston Scientific. Dr Cohen received institutional research grant support from Boston Scientific, Abbott Vascular, and Medtronic and consulting fees from Medtronic and Abbott Vascular. Dr Lombardi received speaking fees and honoraria from Boston Scientific, Abbott Vascular, and Abiomed and consultancy fees for Vascular Solutions, Abbott Vascular, Boston Scientific, Abiomed, and Roxwood Medical. He has Equity in Roxwood Medical and Bridgepoint Medical. His wife is an employee of Spectranetics. Dr Karmpaliotis received speaking fees, honoraria, and consulting fees from Abbott Vascular, Boston Scientific, and Medtronic. Dr Nicholson received speaking fees and honoraria from Boston Scientific and Abbott Vascular. Dr Pershad received speaking fees and honoraria from Boston Scientific Medtronic, Asahi Intecc, Edwards Lifesciences, and Abiomed and consultancy fees for Abiomed and Boston Scientific. Dr Wyman received speaking fees, honoraria, and consulting fees from Boston Scientific and Abbott Vascular. Dr Spaedy received speaking fees and honoraria from Boston Scientific and Abbott Vascular. Dr Cook received speaking fees and honoraria from Boston Scientific and Abbott Vascular. Dr Doshi received speaking fees and consulting fees from Boston Scientific and Abbott Vascular; consulting fees from CSI, Medtronic, and Spectranetics; and research grants from Boston Scientific. Dr Federici received honoraria from Boston Scientific. Dr Spertus received research grants from Lilly, Gilead, and Abbott Vascular, and consultancy fees for Novartis, Amgen, Regeneron, and United Healthcare. He owns the copyright to the Seattle Angina Questionnaire, Kansas City Cardiomyopathy Questionnaire, and PAQ and has an equity interest in Health Outcomes Sciences. Dr Salisbury received institutional research grants from Boston Scientific and Gilead and speaking fees or honoraria from Abbott, Abiomed, and Medtronic. The other authors report no conflicts.
Funding Information:
OPEN-CTO study (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures) was supported by research grant from Boston Scientific.
Publisher Copyright:
© 2019 American Heart Association, Inc.
PY - 2019
Y1 - 2019
N2 - BACKGROUND: Health status and quality of life improvement after chronic total occlusion (CTO) percutaneous coronary intervention (PCI) among patients with refractory angina has not been reported. We sought to determine the degree of quality of life improvement after CTO PCI in patients with refractory angina. METHODS AND RESULTS: Among 1000 consecutive patients who underwent CTO PCI in a 12-center registry, refractory angina was defined as any angina (baseline Seattle Angina Questionnaire [SAQ] Angina Frequency score of ≤90) despite treatment with ≥3 antianginal medications. Health status at baseline and 1-year follow-up was quantified using the SAQ. Refractory angina was present at baseline in 148 patients (14.8%). Technical success was achieved in 120 (81.1%) at the initial attempt and major adverse cardiac and cerebral events occurred in 10 (6.8%). There were no procedural deaths. Refractory angina patients were highly symptomatic at baseline with mean SAQ Angina Frequency of 51.1±23.8, SAQ quality of life of 35.3±21.2, and SAQ Summary Score of 47.2±17.9, improving by 32.0±27.8, 35.7±23.9, and 32.1±20.1 at 1 year. Through 1-year follow-up, patients with successful CTO PCI had significantly larger degree of improvement of SAQ Angina Frequency and SAQ Summary Score (35.0±26.8 versus 18.8±28.9, P<0.01; 34.2±19.4 versus 22.5±20.8, P<0.01) compared with unsuccessful CTO PCI. CONCLUSIONS: Refractory angina was present in 1 of 7 patients in the OPEN-CTO (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures) registry. Patients with refractory angina experienced large, clinically significant health status improvements that persisted through 12 months, and patients with successful CTO PCI had larger health status improvement than those without.
AB - BACKGROUND: Health status and quality of life improvement after chronic total occlusion (CTO) percutaneous coronary intervention (PCI) among patients with refractory angina has not been reported. We sought to determine the degree of quality of life improvement after CTO PCI in patients with refractory angina. METHODS AND RESULTS: Among 1000 consecutive patients who underwent CTO PCI in a 12-center registry, refractory angina was defined as any angina (baseline Seattle Angina Questionnaire [SAQ] Angina Frequency score of ≤90) despite treatment with ≥3 antianginal medications. Health status at baseline and 1-year follow-up was quantified using the SAQ. Refractory angina was present at baseline in 148 patients (14.8%). Technical success was achieved in 120 (81.1%) at the initial attempt and major adverse cardiac and cerebral events occurred in 10 (6.8%). There were no procedural deaths. Refractory angina patients were highly symptomatic at baseline with mean SAQ Angina Frequency of 51.1±23.8, SAQ quality of life of 35.3±21.2, and SAQ Summary Score of 47.2±17.9, improving by 32.0±27.8, 35.7±23.9, and 32.1±20.1 at 1 year. Through 1-year follow-up, patients with successful CTO PCI had significantly larger degree of improvement of SAQ Angina Frequency and SAQ Summary Score (35.0±26.8 versus 18.8±28.9, P<0.01; 34.2±19.4 versus 22.5±20.8, P<0.01) compared with unsuccessful CTO PCI. CONCLUSIONS: Refractory angina was present in 1 of 7 patients in the OPEN-CTO (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures) registry. Patients with refractory angina experienced large, clinically significant health status improvements that persisted through 12 months, and patients with successful CTO PCI had larger health status improvement than those without.
KW - Chronic total occlusion
KW - Dyspnea
KW - Health status
KW - Percutaneous coronary intervention
KW - Quality of life
KW - Refractory angina
KW - Registry
UR - http://www.scopus.com/inward/record.url?scp=85062969652&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062969652&partnerID=8YFLogxK
U2 - 10.1161/CIRCINTERVENTIONS.118.007558
DO - 10.1161/CIRCINTERVENTIONS.118.007558
M3 - Article
C2 - 30871356
AN - SCOPUS:85062969652
SN - 1941-7640
VL - 12
JO - Circulation: Cardiovascular Interventions
JF - Circulation: Cardiovascular Interventions
IS - 3
M1 - e007558
ER -